The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

To learn more, please visit www.reprievetrial.org.